KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Novavax (NVAX) Receivables - Other (2020 - 2025)

Novavax has reported Receivables - Other over the past 12 years, most recently at $10.8 million for Q4 2025.

  • Quarterly results put Receivables - Other at $10.8 million for Q4 2025, up 100.0% from a year ago — trailing twelve months through Dec 2025 was $10.8 million (up 100.0% YoY), and the annual figure for FY2025 was $10.8 million, up 100.0%.
  • Receivables - Other for Q4 2025 was $10.8 million at Novavax, up from $5.2 million in the prior quarter.
  • Over the last five years, Receivables - Other for NVAX hit a ceiling of $68.0 million in Q3 2022 and a floor of $200000.0 in Q1 2024.
  • Median Receivables - Other over the past 5 years was $25.0 million (2021), compared with a mean of $26.1 million.
  • Biggest five-year swings in Receivables - Other: crashed 99.53% in 2024 and later skyrocketed 2950.0% in 2025.
  • Novavax's Receivables - Other stood at $35.3 million in 2021, then decreased by 18.98% to $28.6 million in 2022, then crashed by 62.24% to $10.8 million in 2023, then crashed by 50.0% to $5.4 million in 2024, then skyrocketed by 100.0% to $10.8 million in 2025.
  • The last three reported values for Receivables - Other were $10.8 million (Q4 2025), $5.2 million (Q3 2025), and $5.3 million (Q2 2025) per Business Quant data.